FGF21 is Required for the Metabolic Benefits of IKKε/TBK1 Inhibition

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2021 Apr 6

PMID 33822771

Citations 3

Authors

Shannon M Reilly

Mohammad Abu-Odeh

Magdalene Ameka

Julia H DeLuca

Meghan C Naber

Benyamin Dadpey

Nima Ebadat

Andrew V Gomez

Xiaoling Peng

BreAnne Poirier

Elyse Walk

Matthew J Potthoff

Alan R Saltiel

Affiliations

Soon will be listed here.

Abstract

The protein kinases IKKε and TBK1 are activated in liver and fat in mouse models of obesity. We have previously demonstrated that treatment with the IKKε/TBK1 inhibitor amlexanox produces weight loss and relieves insulin resistance in obese animals and patients. While amlexanox treatment caused a transient reduction in food intake, long-term weight loss was attributable to increased energy expenditure via FGF21-dependent beiging of white adipose tissue (WAT). Amlexanox increased FGF21 synthesis and secretion in several tissues. Interestingly, although hepatic secretion determined circulating levels, it was dispensable for regulating energy expenditure. In contrast, adipocyte-secreted FGF21 may have acted as an autocrine factor that led to adipose tissue browning and weight loss in obese mice. Moreover, increased energy expenditure was an important determinant of improved insulin sensitivity by amlexanox. Conversely, the immediate reductions in fasting blood glucose observed with acute amlexanox treatment were mediated by the suppression of hepatic glucose production via activation of STAT3 by adipocyte-secreted IL-6. These findings demonstrate that amlexanox improved metabolic health via FGF21 action in adipocytes to increase energy expenditure via WAT beiging and that adipocyte-derived IL-6 has an endocrine role in decreasing gluconeogenesis via hepatic STAT3 activation, thereby producing a coordinated improvement in metabolic parameters.

Citing Articles

Can Exercise-Mediated Adipose Browning Provide an Alternative Explanation for the Obesity Paradox?.

Zhao J, Li X, Liang C, Yan Y Int J Mol Sci. 2025; 26(5).

PMID: 40076419 PMC: 11898606. DOI: 10.3390/ijms26051790.

Berberine-induced browning and energy metabolism: mechanisms and implications.

Alpaslan Agacdiken A, Goktas Z PeerJ. 2025; 13:e18924.

PMID: 39931072 PMC: 11809318. DOI: 10.7717/peerj.18924.

FGF-based drug discovery: advances and challenges.

Chen G, Chen L, Li X, Mohammadi M Nat Rev Drug Discov. 2025; .

PMID: 39875570 DOI: 10.1038/s41573-024-01125-w.

Lack of p38 activation in T cells increases IL-35 and protects against obesity by promoting thermogenesis.

Nikolic I, Ruiz-Garrido I, Crespo M, Romero-Becerra R, Leiva-Vega L, Mora A EMBO Rep. 2024; 25(6):2635-2661.

PMID: 38730210 PMC: 11169359. DOI: 10.1038/s44319-024-00149-y.

The TBK1/IKKε inhibitor amlexanox improves dyslipidemia and prevents atherosclerosis.

Zhao P, Sun X, Liao Z, Yu H, Li D, Shen Z JCI Insight. 2022; 7(17).

PMID: 35917178 PMC: 9536260. DOI: 10.1172/jci.insight.155552.

References

Hotamisligil G . Inflammation and metabolic disorders. Nature. 2006; 444(7121):860-7. DOI: 10.1038/nature05485. View

Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V . Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 2007; 5(6):415-25. DOI: 10.1016/j.cmet.2007.05.003. View

Neinast M, Frank A, Zechner J, Li Q, Vishvanath L, Palmer B . Activation of natriuretic peptides and the sympathetic nervous system following Roux-en-Y gastric bypass is associated with gonadal adipose tissues browning. Mol Metab. 2015; 4(5):427-36. PMC: 4421080. DOI: 10.1016/j.molmet.2015.02.006. View

Chiang S, Bazuine M, Lumeng C, Geletka L, Mowers J, White N . The protein kinase IKKepsilon regulates energy balance in obese mice. Cell. 2009; 138(5):961-75. PMC: 2756060. DOI: 10.1016/j.cell.2009.06.046. View

MacDougald O . Methods in Enzymology. Methods of adipose tissue biology, part B. Preface. Methods Enzymol. 2014; 538:xv. DOI: 10.1016/B978-0-12-800280-3.09987-4. View

Saltiel A . New therapeutic approaches for the treatment of obesity. Sci Transl Med. 2016; 8(323):323rv2. DOI: 10.1126/scitranslmed.aad1811. View

Wei W, Dutchak P, Wang X, Ding X, Wang X, L Bookout A . Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ. Proc Natl Acad Sci U S A. 2012; 109(8):3143-8. PMC: 3286969. DOI: 10.1073/pnas.1200797109. View

Oral E, Reilly S, Gomez A, Meral R, Butz L, Ajluni N . Inhibition of IKKɛ and TBK1 Improves Glucose Control in a Subset of Patients with Type 2 Diabetes. Cell Metab. 2017; 26(1):157-170.e7. PMC: 5663294. DOI: 10.1016/j.cmet.2017.06.006. View

Saltiel A, Olefsky J . Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest. 2017; 127(1):1-4. PMC: 5199709. DOI: 10.1172/JCI92035. View

10.

Isobe A, Takeda T, Sakata M, Yamamoto T, Minekawa R, Hayashi M . STAT3-mediated constitutive expression of SOCS3 in an undifferentiated rat trophoblast-like cell line. Placenta. 2005; 27(8):912-8. DOI: 10.1016/j.placenta.2005.10.003. View

11.

Reilly S, Ahmadian M, Zamarron B, Chang L, Uhm M, Poirier B . A subcutaneous adipose tissue-liver signalling axis controls hepatic gluconeogenesis. Nat Commun. 2015; 6:6047. PMC: 4324568. DOI: 10.1038/ncomms7047. View

12.

Inoue H, Ogawa W, Asakawa A, Okamoto Y, Nishizawa A, Matsumoto M . Role of hepatic STAT3 in brain-insulin action on hepatic glucose production. Cell Metab. 2006; 3(4):267-75. DOI: 10.1016/j.cmet.2006.02.009. View

13.

Reilly S, Chiang S, Decker S, Chang L, Uhm M, Larsen M . An inhibitor of the protein kinases TBK1 and IKK-ɛ improves obesity-related metabolic dysfunctions in mice. Nat Med. 2013; 19(3):313-21. PMC: 3594079. DOI: 10.1038/nm.3082. View

14.

Weissmann L, Quaresma P, Santos A, de Matos A, Pascoal V, Zanotto T . IKKε is key to induction of insulin resistance in the hypothalamus, and its inhibition reverses obesity. Diabetes. 2014; 63(10):3334-45. DOI: 10.2337/db13-1817. View

15.

Reilly S, Saltiel A . Adapting to obesity with adipose tissue inflammation. Nat Rev Endocrinol. 2017; 13(11):633-643. DOI: 10.1038/nrendo.2017.90. View

16.

Knowler W, Pettitt D, Saad M, BENNETT P . Diabetes mellitus in the Pima Indians: incidence, risk factors and pathogenesis. Diabetes Metab Rev. 1990; 6(1):1-27. DOI: 10.1002/dmr.5610060101. View

17.

Zatterale F, Longo M, Naderi J, Raciti G, Desiderio A, Miele C . Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes. Front Physiol. 2020; 10:1607. PMC: 7000657. DOI: 10.3389/fphys.2019.01607. View

18.

Talukdar S, Zhou Y, Li D, Rossulek M, Dong J, Somayaji V . A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects. Cell Metab. 2016; 23(3):427-40. DOI: 10.1016/j.cmet.2016.02.001. View

19.

Ramadoss P, Unger-Smith N, Lam F, Hollenberg A . STAT3 targets the regulatory regions of gluconeogenic genes in vivo. Mol Endocrinol. 2009; 23(6):827-37. PMC: 5419286. DOI: 10.1210/me.2008-0264. View

20.

Kazak L, Chouchani E, Stavrovskaya I, Lu G, Jedrychowski M, Egan D . UCP1 deficiency causes brown fat respiratory chain depletion and sensitizes mitochondria to calcium overload-induced dysfunction. Proc Natl Acad Sci U S A. 2017; 114(30):7981-7986. PMC: 5544316. DOI: 10.1073/pnas.1705406114. View